Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors.Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action.Here we show that Gleevec can act on host DCs to promote NK cell activation.DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT.Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner.Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response.These data point to a novel mode of antitumor action for Gleevec.Nonstandard abbreviations used: bi-injection daily (bid); bone marrow-derived DC (BM-DC); break point cluster region/Abelson leukemia virus (BCR/ABL); chronic myelogenous leukemia (CML); c-kit loss-of-function mutation (W/Wv); fms-like tyrosine 3 kinase ligand (FL); gastrointestinal stromal tumor (GIST); progression-free survival (PFS); stem cell factor (SCF); transporter associated with antigen processing (TAP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Borg et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389 · cited 1×
“Gleevec administration results in objective (partial or complete) response or stabilization in about 80% of GIST patients (6).”
BackgroundSelf-citationEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“The renaissance of interest in NK cells in tumor immunosurveillance can be attributed to the discovery of stressinduced ligands for receptors that activate NK cells (23–25) and to the relevance of interactions between MHC class I molecules and killer inhibitory receptors in mismatched hematopoietic transplants, which…”
BackgroundActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301 · cited 1×
“Somatic gain-of-function mutations of the c-kit protooncogene are found in 85% of GISTs (1), and recently, mutations of the PDGFRα chain were reported in 35% of the GISTs lacking the KIT mutations (2).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299 · cited 4×
“GISTs harboring an exon 11 mutation (76% of GISTs) exhibit the highest objective response rate and the longest time to progression (7).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592 · cited 1×
“Notably, in 50% of GIST-bearing patients, a fraction of circulating NK cells showed a downregulation of NKG2D expression at diagnosis (data not shown), which suggests that GISTs secrete soluble NKG2D ligands that might downregulate NKG2D expression on blood NK cells, similarly to the downregulation seen on T cells (30…”
BackgroundCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,115 · cited 6×
“Since FL is known to amplify DCs, (14) and since mature DCs have the unique capacity to promote NK cell effector functions including IFN-γ secretion and antitumor effects in vivo (10, 15), we hypothesized that Gleevec could confer an NK cell stimulatory capacity to host DCs. Gleevec enhanced IFN-γ production by NK cel…”
BackgroundInfluentialRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Research works printed but not linked: 1
- Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intes- tinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.
Cited by
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
“…et al., 2013 promotes an activatory crosstalk between DCs and NK cells results in therapeutically relevant secretion of IFNg by NK cells Borg et al., 2004; Delahaye et al., 2011 favors the relative accumulation of M2 TAMs KIT-dependent effect Cavnar et al., 2013 human cancer cells…”
BackgroundCancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
“Similarly, imatinib mesylate can stimulate the activity of NK cells, correlating with a favourable clinical outcome for patients with gastrointestinal stromal tumour”
BackgroundTargeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
“DCs propagated in GM-CSF and IL-4 were obtained as previously described (20).”
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
“…of specific isoforms of the NK cell-activating receptor NKp30 (Delahaye et al., 2011), the imatinib-induced production of interferon-g (IFN-g) by circulating NK cells (Borg et al., 2004; Ménard et al., 2009), as well as the frequency of tumor-infiltrating NK cells (Rusakiewicz et al., 2013).”
BackgroundInfluentialThe role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
“these TKIs have multiple targets such as c-Kit and PDGFR that can have a direct impact on immune cells such as DC, natural killer (NK), and others (35, 36).”
BackgroundSelf-citationImmune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
“Imatinib may inhibit the in vivo growth of murine tumor cells that do not respond in vitro , and this in vivo effect relies on the activation of natural killer cells”
BackgroundNatural-killer cells and dendritic cells: “l'union fait la force”
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., & Vivier, E. (2005) · Blood · doi:10.1182/blood-2005-03-1154 · Cited by 634
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Close encounters of different kinds: Dendritic cells and NK cells take centre stage
Degli-Esposti, M. A., & Smyth, M. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1549 · Cited by 554
“and in sites of imatinib (Gleevec)-induced lichenoid dermatiti”
BackgroundBalachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
“Imatinib has also been shown to induce dendritic cells to activate NK cells in mice with other tumor”
BackgroundViaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
“1 mAb (PK136) or isotype control Ab at day-4, day0 and day+4 as described elsewhere [79].”
MethodCD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
“Tumor immunity is not only T cell dependent; recently, a number of studies in leukemia (12), lymphoma (13), and gastrointestinal stromal tumors (14) revealed that NK cell activation and cytotoxicity influence patient outcome.”
BackgroundA novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
“However, unexpected long-term responses to imatinib mesylate have been reported for individuals with GIST whose tumors were predicted to resist this treatmen”
BackgroundImmunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
Effector and regulatory events during natural killer–dendritic cell interactions
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., & Moretta, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00450.x · Cited by 304
“Reports have described NK cells in close contact with DCs in lesions of atopic eczema/dermatitis syndrome and also in Gleevec-induced lichenoid dermatitis in patients with gastrointestinal stromal tumor (53, 54).”
BackgroundNatural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
“Gastrointestinal stromal tumors (GIST), which are mostly caused by activating mutations in the receptor tyrosine kinases c-Kit or platelet derived growth factor receptor-α, show molecular features of NK cell sensitivity in vitro”
BackgroundHipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., & Brossart, P. (2008) · Blood · doi:10.1182/blood-2007-02-075945 · Cited by 288
Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
“We found that IM can promote the DC/NK cell cross talk in vivo and in vitro inmouse and human settings (65).”
BackgroundInfluentialCarpenter, P. A., Snyder, D., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2006-04-019836 · Cited by 226
“Median age, y (range) 37 (4-49) 44 (24-62)”
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Self-citationActivation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma
Krishnamoorthy, N., Oriss, T. B., Paglia, M., Fei, M., Yarlagadda, M., Vanhaesebroeck, B., Ray, A., & Ray, P. (2008) · Nature Medicine · doi:10.1038/nm1766 · Cited by 210
Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202
“We unraveled the natural killer (NK) cell–dependent antitumor effects promoted by IM-treated DC in mouse tumor models resistant to the IM antiproliferative effects in vitro (11).”
BackgroundResultInfluentialSelf-citationDendritic-cell-based therapeutic vaccination against cancer
Nestle, F. O., Farkas, A., & Conrad, C. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.02.003 · Cited by 199
“The c-kit tyrosine kinase inhibitor imatinib mesylate has been shown to act on host DCs to promote NK activation and enhanced anti-tumor responses [55].”
BackgroundDraghi, M., Pashine, A., Sanjanwala, B., Gendzekhadze, K., Cantoni, C., Cosman, D., Moretta, A., Valiante, N. M., & Parham, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2688 · Cited by 200
“Sites of NK-DC interactions may be either lymphoid organs (20–24) or nonlymphoid peripheral tissues (25, 26).”
BackgroundChemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
“Our own studies indicate that the paradigmatic c-kit tyrosine inase inhibitor imatinib mesylate (IM) boosts IFN- secretion by K cells, both inmice and in GIST patients [54,55].”
BackgroundNK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
“Abundant preclinical data indicate that NK cells not only participate in cancer immunosurveillance (at least in some tumors) [7–9], but also support therapeutic responses as elicited by a variety of treatments, including chemotherapy [10, 11], radiation therapy (RT) [12, 13], targeted anticancer agents [14, 15], and p…”
BackgroundCancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Ménard, C., Martin, F., Apetoh, L., Bouyer, F., & Ghiringhelli, F. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0505-6 · Cited by 167
“previously described that imatinib mesylate (IM), a tyrosine kinase inhibitor, in association with its direct antitumor eVect could also stimulate NK functions in Gastro-Intestinal Stromal Tumor (GIST)bearing patients [47].”
BackgroundNatural killer cell immune escape in acute myeloid leukemia
Lion, E., Willemen, Y., Berneman, Z. N., Van Tendeloo, V. F. I., & Smits, E. L. J. (2012) · Leukemia · doi:10.1038/leu.2012.87 · Cited by 164
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Larmonier, N., Janikashvili, N., LaCasse, C. J., Larmonier, C. B., Cantrell, J., Situ, E., Lundeen, T., Bonnotte, B., & Katsanis, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6955 · Cited by 160
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Semeraro, M., Rusakiewicz, S., Minard-Colin, V., Delahaye, N. F., Enot, D., Vély, F., Marabelle, A., Papoular, B., Piperoglou, C., Ponzoni, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2327 · Cited by 153
Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.-M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.-X., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5108 · Cited by 148
Dendritic cell derived-exosomes: biology and clinical implementations
Chaput, N., Flament, C., Viaud, S., Taieb, J., Roux, S., Spatz, A., André, F., LePecq, J.-B., Boussac, M., Garin, J., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0206094 · Cited by 148
“vival in cancer-bearing patients [56–58].”
Kim, D. H., Kamel‐Reid, S., Chang, H., Sutherland, R., Jung, C. W., Kim, H.-J., Lee, J.-J., & Lipton, J. H. (2008) · Haematologica · doi:10.3324/haematol.13151 · Cited by 145
“It has also been shown that IM treatment can induce NK cell activation which correlates with enhanced response against gastrointestinal stromal tumors (GISTs).(18) Moreover, the same group has shown that IM treatment in mice can induce selective expansion of IFN-producing killer dendritic cells (IKDC).”
BackgroundImmunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Self-citationCancer chemotherapy: A critical analysis of its 60 years of history
Galmarini, D., Galmarini, C. M., & Galmarini, F. C. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.002 · Cited by 151
“These ffects are apparently mediated by the action of imatinib on ost dendritic cells that activate and enhance natural killer ntitumor activity, which positively correlated with clinical utcome [161,162].”
BackgroundImmune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 163
“Similarly, imatinib efficacy is dependent on NK cells in melanoma metastasis models [128], whereas CD8 T cells contribute to tumor regression following imatinib treatment of GIST-bearing mice or dasatinib treatment of subcutaneous mastocytoma-bearing mice [129, 130].”
BackgroundTanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
“promoted DC-dependent natural killer cell activation (21), and”
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
D'Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2349 · Cited by 131
“Imatinib, specifically, can trigger NK cells in mice and humans, promoting its antiproliferative effects.(16) These effects have been associated with improved preclinical(13) and clinical outcomes with these agents.”
BackgroundImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Hughes, A., & Yong, A. S. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00469 · Cited by 144
“Imatinib activates CD8+ T cells and NK cells and leads to apoptosis of immunosuppressive Treg (23, 119).”
BackgroundThe role of mast cells in cancers
Maciel, T. T., Moura, I. C., & Hermine, O. (2015) · F1000Prime Reports · doi:10.12703/p7-09 · Cited by 123
“Results obtained with KIT-dependent mast cell-deficient mice should be viewed with caution, since these mice also present other abnormalities related to c-kit mutations, which may affect other cells involved in tumor progression (including natural killer [NK] and dendritic cells) [57,58].”
BackgroundWolf, A. M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., Weiss, G., & Tilg, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501758102 · Cited by 124
Moving towards dose individualization of tyrosine kinase inhibitors
Klümpen, H., Samer, C. F., Mathijssen, R. H. J., Schellens, J. H. M., & Gurney, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.006 · Cited by 140
van Dongen, M., Savage, N. D. L., Jordanova, E. S., Briaire‐de Bruijn, I. H., Walburg, K. V., Ottenhoff, T. H. M., Hogendoorn, P. C. W., van der Burg, S. H., Gelderblom, H., & van Hall, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25113 · Cited by 118
Ayach, B., Yoshimitsu, M., Dawood, F., Sun, M., Arab, S., Chen, M., Higuchi, K., Siatskas, C., Lee, P. C., Lim, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510997103 · Cited by 115
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Boehrer, S., Adès, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., Roux, G. L., Gardin, C., Martin, A., de Botton, S., et al. (2007) · Blood · doi:10.1182/blood-2007-07-100362 · Cited by 124
Issels, R. D., Kampmann, E., Kanaar, R., & Lindner, L. H. (2016) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1119317 · Cited by 125
“This direct anti-proliferative effect is coupled with an additional ‘off-target’ effect that induces dendritic cell (DC)mediated natural killer (NK) cell activation [25].”
BackgroundInfusions of Allogeneic Natural Killer Cells as Cancer Therapy
Leung, W. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1766 · Cited by 120
Natural killer cell–dendritic cell crosstalk in the initiation of immune responses
Walzer, T., Dalod, M., Vivier, É., & Zitvogel, L. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.s49 · Cited by 104
“2 NK-cell-mediated tumour rejection via DCs Modulation of the c-kit signalling pathway in DCs leads to marked NK-cell activation in various strains of mice [53].”
BackgroundInfluentialEfficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)
Stacchiotti, S., Pantaleo, M. A., Negri, T., Astolfi, A., Tazzari, M., Dagrada, G. P., Urbini, M., Indio, V., Maestro, R., Gronchi, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1243 · Cited by 100
“This is standard practice in metastatic gastrointestinal stromal tumor (GIST) surgically excised of IM-responding lesions (32).”
Sampaio, M. M., Santos, M. L. C., Marques, H. S., Gonçalves, V. L. D. S., Araújo, G. R. L., Lopes, L. W., Apolonio, J. S., Silva, C. S., Santos, L. K. D. S., Cuzzuol, B. R., et al. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i2.69 · Cited by 117
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
Meng, D., & Carvajal, R. D. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0414-1 · Cited by 97
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 98
“Imatinib mesylate (Gleevec), a speciWc inhibitor of tyrosine kinase receptors may also lead to host-anti tumor eVects mediated by the innate immune system and a new type of immune cell, referred to as IFN-producing killer dendritic cells (IKDC) that resemble natural killer cells [7, 113, 123].”
Present and Future of Allogeneic Natural Killer Cell Therapy
Lim, O., Jung, M. Y., Hwang, Y. K., & Shin, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00286 · Cited by 97
“In addition, c-kit tyrosine kinase inhibitor (67) and JAK inhibitors (68) increase the susceptibility of tumor cells to NK cytotoxicity and enhance antitumor responses by increased IFN-γ production from NK cells.”
BackgroundNK Cells: Key to Success of DC-Based Cancer Vaccines?
Lion, E., Smits, E., Berneman, Z. N., & Tendeloo, V. F. V. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0122 · Cited by 94
“Prognostic and predictive NK cell parameters NK cell parameter Association Malignancy Extensive NK cell tumor infiltration, high frequency of circulating NK cells Favorable outcome Lung cancer [154, 155], colorectal cancer [143, 156–158], gastric cancer [159], renal cancer [142, 160], AML [138] NK cell cytolytic activ…”
BackgroundDendritic Cell-NK Cell Cross-Talk: Regulation and Physiopathology
Zitvogel, L., Terme, M., Borg, C., & Trinchieri, G. (2005) · Springer eBooks · doi:10.1007/3-540-27743-9_8 · Cited by 94
“A direct contact between DC and NK cells was first shown in Malassezia-induced atopic skin lesions [52] and later highlighted in imatinib mesylate (Gleevec/STI571)-induced lichenoid dermatitis [ 53 ].”
BackgroundInfluentialEffects of Imatinib on Normal Hematopoiesis and Immune Activation
Appel, S., Balabanov, S., Brümmendorf, T. H., & Brossart, P. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0069 · Cited by 92
Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 91
Natural killer cells in viral infection: more than just killers
Andoniou, C. E., Andrews, D. M., & Degli‐Esposti, M. A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00465.x · Cited by 87
“DCs are predicted to interact with other cellular effectors at sites of inflammation or infection, and contact between DCs and NK cells has been observed in skin lesions from atopic eczema/dermatitis syndrome patients (161, 162) and in Gleevec-induced lichenoid dermatitis (163).”
BackgroundThe Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 96
“Targeted drugs such as imatinib mesylate or bortezomib can restore the DC–tumor interaction in favor of the host (Borg et al., 2004; Spisek et al., 2007), whereas combination of classical anticancer treatments with immunomodulators (GADD34/PP1 inhibitors, chloroquine) could potentially induce or re-establish the immun…”
BackgroundPittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010) · Oncogene · doi:10.1038/onc.2010.494 · Cited by 96
“Oncogene objective clinical responses to imatinib treatment and that several mouse tumor cell lines are sensitive to the antiproliferative effect of imatinib only in vivo but not in vitro (Borg et al., 2004).”
InfluentialAdenis, A., Blay, J., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Dômont, J., Ray-Coquard, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu237 · Cited by 84
“It has been suggested that innate immunity plays a role in GIST disease progression; the survival of GIST patients correlating positively with increased activity of natural killer cells [15, 16].”
BackgroundTargeted Therapy and Immunosuppression in the Tumor Microenvironment
Allegrezza, M. J., & Conejo-Garcia, J. R. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.009 · Cited by 81
PDL1 expression is an independent prognostic factor in localized GIST
Bertucci, F., Finetti, P., Mamessier, É., Pantaleo, M. A., Astolfi, A., Ostrowski, J., & Birnbaum, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002729 · Cited by 83
Chretien, A.-S., Le Roy, A., Vey, N., Prebet, T., Blaise, D., Fauriat, C., & Olive, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00122 · Cited by 79
“IMPROVING NK/DC CROSSTALK The relevance of the NK/DC crosstalk has been demonstrated in various physiopathological settings and alterations of these interactions have been shown to contribute to tumor progression (145).”
BackgroundImmunomodulatory effects of anti-angiogenic drugs
Heine, A., Held, S., Bringmann, A., Holderried, T. A. W., & Brossart, P. (2011) · Leukemia · doi:10.1038/leu.2011.24 · Cited by 79
He, S., Yin, T., Li, D., Gao, X., Wan, Y., Ma, X., Ye, T., Guo, F., Sun, J., Lin, Z., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-186 · Cited by 75
“Imatinib can act on host DCs to promote NK cell activation [30].”
The renaissance of anti‐neoplastic immunity from tumor cell demise
Ma, Y., Pitt, J. M., Li, Q., & Yang, H. (2017) · Immunological Reviews · doi:10.1111/imr.12586 · Cited by 73
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
Smalley, K. S. M., Sondak, V. K., & Weber, J. S. (2009) · PubMed · doi:10.14670/hh-24.643 · Cited by 73
Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity
Napier, R. J., Norris, B. A., Swimm, A. I., Giver, C. R., Harris, W. A. C., Laval, J., Napier, B. A., Patel, G., Crump, R., Peng, Z., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004770 · Cited by 76
“Thus, imatinib remains effective in vivo even against engrafted GIST cells that are unresponsive to the drug in vitro, an effect attributed to stimulation of cross talk between dendritic cells and natural killer cells, which have attendant anti-tumor activity [35].”
BackgroundHarnessing dendritic cells in cancer
Apétoh, L., Locher, C., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.01.003 · Cited by 89
Innate Immune Recognition and Suppression of Tumors
Hayakawa, Y., & Smyth, M. J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95008-8 · Cited by 83
The ‘kiss of death’ by dendritic cells to cancer cells
Chan, C. W., & Housseau, F. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402235 · Cited by 81
Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
Iyoda, M., Shibata, T., Hirai, Y., Kuno, Y., & Akizawa, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111158 · Cited by 66
Emerging functions of c-kit and its ligand stem cell factor in dendritic cells
Ray, P., Krishnamoorthy, N., & Ray, A. (2008) · Cell Cycle · doi:10.4161/cc.7.18.6752 · Cited by 66
Signaling of c‐kit in dendritic cells influences adaptive immunity
Ray, P., Krishnamoorthy, N., Oriss, T. B., & Ray, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05122.x · Cited by 77
Combining cancer immunotherapy and targeted therapy
Ribas, A., & Wolchok, J. D. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.011 · Cited by 65
“This effect was mediated by the activation of favorable cross-talk between DC and NK cells [50,51].”
Dendritic Cell Interactions with NK Cells from Different Tissues
Ferlazzo, G., & Münz, C. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9283-y · Cited by 68
“This hypothetical interaction is supported by in vivo observations, where NK cells have been found in close contact with DCs either in lesions of atopic eczema/dermatitis syndrome or in Gleevec-induced lichenoid dermatitis in gastrointestinal stromal tumor (GIST) bearing patients [28, 29].”
ResultExacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice
Piconese, S., Costanza, M., Musio, S., Tripodo, C., Poliani, P. L., Gri, G., Burocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., et al. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.3 · Cited by 66
“45 C-Kit pharmacological inhibition fosters a productive cross-talk between DCs and natural killer (NK) cells”
BackgroundAnticancer immunochemotherapy using adjuvants with direct cytotoxic effects
Zitvogel, L., & Kroemer, G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39991 · Cited by 64
Ott, P. A., & Adams, S. (2011) · Immunotherapy · doi:10.2217/imt.10.99 · Cited by 67
“Imatinib was found to increase the NK stimulatory capacity of DC in mice and lead to greater NK cell activation in patients with GIST, correlating with improved tumor response [97].”
BackgroundSaito, H., Osaki, T., & Ikeguchi, M. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0059-8 · Cited by 69
“In fact, NK cells may participate in tumor immune surveillance, particularly in leukemia [31], neuroblastoma [32], and gastrointestinal stromal tumors [33].”
BackgroundRussick, J., Torset, C., Hemery, E., & Cremer, I. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101407 · Cited by 64
Longo, V., Brunetti, O., Azzariti, A., Galetta, D., Nardulli, P., Leonetti, F., & Silvestris, N. (2019) · Cancers · doi:10.3390/cancers11040539 · Cited by 66
“It is well known that this drug induces NK cells activity through DCs in several cancers [100,101].”
BackgroundEffect of splenectomy on antitumor immune system in mice.
Higashijima, J., Shimada, M., Chikakiyo, M., Miyatani, T., Yoshikawa, K., Nishioka, M., Iwata, T., & Kurita, N. (2009) · PubMed · Cited by 70
Pantaleo, M. A., Tarantino, G., Agostinelli, C., Urbini, M., Nannini, M., Saponara, M., Castelli, C., Stacchiotti, S., Fumagalli, E. R., Gatto, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1617588 · Cited by 62
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma
Vieyra-Garcia, P. A., Crouch, J. D., O’Malley, J. T., Seger, E. W., Yang, C., Teague, J. E., Vromans, A. M., Gehad, A. E., Win, T. S., Yu, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124233 · Cited by 58
“of NK cells, and enhanced antitumor immunity (27).”
BackgroundZhang, Q., Sun, H., Zhang, K., Jia, Q., Bu, Y., Wang, M., Chai, Z., Zhang, Q., Wang, W., Kong, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055945 · Cited by 59
Links between innate and cognate tumor immunity
Ghiringhelli, F., Apétoh, L., Housseau, F., Kroemer, G., & Zitvogel, L. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.003 · Cited by 64
Rusakiewicz, S., Perier, A., Semeraro, M., Pitt, J. M., von Strandmann, E. P., Reiners, K. S., Aspeslagh, S., Pipéroglou, C., Vely, F., Ivagnès, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1137418 · Cited by 64
“IM targets KIT receptors on dendritic cells (DC), unleashing theDC/NK cell cross-talk, leading toNK cell activation with Th1 cytokine release and enhanced cytotoxicity inmice and humans.(8) We previously reported that by 2 months of IM, the increased IFN-g secretion from circulating NK cells correlated with prolonged…”
BackgroundAdvances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Li, B., Chen, H., Yang, S., Chen, F., Xu, L., Li, Y., Li, M., Zhu, C., Shao, F., Zhang, X., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01770-6 · Cited by 69
Metadata
- Authors
- Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Cesne, A. L., Chung-Scott, V., Lazar, V., Tchou, I., Crépineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J.-Y., Spatz, A., Emile, J.-F., Heinrich, M. C., Mécheri, S., Tursz, T., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- National Cancer Centre Japan (JP)
- Vrije Universiteit Brussel (BE)
- Institut Gustave Roussy (FR)
- Institut Jean Godinot (FR)
- Harvard University (US)
- Hospices Civils de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Oregon Health & Science University (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-01
- Volume
- 114
- Issue
- 3
- Pages
- 379-388
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC489961
- OpenAlex
- W2161785083
- Cited by
- 302
- References
- 35
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 19
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Institut National de la Santé et de la Recherche Médicale
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, NK cell activation, dendritic cells, interferon-gamma, antitumor immunity, PDGF receptor, stem cell factor
- MeSH terms
- Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Dendritic Cells, Enzyme Inhibitors, Female, Gastrointestinal Neoplasms, Humans, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Longitudinal Studies, Mice, Inbred C57BL, Mutation, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Gene Expression Regulation, Neoplastic, Case-Control Studies, Mice, SCID, Stromal Cells, Receptors, Platelet-Derived Growth Factor, Mice, Knockout, Neutrophil Activation, Coculture Techniques, Proto-Oncogene Proteins c-kit, Receptor Protein-Tyrosine Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.